1. Home
  2. RICK vs CBIO Comparison

RICK vs CBIO Comparison

Compare RICK & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RCI Hospitality Holdings Inc.

RICK

RCI Hospitality Holdings Inc.

HOLD

Current Price

$24.85

Market Cap

207.0M

ML Signal

HOLD

CBIO

Crescent Biopharma Inc.

HOLD

Current Price

$13.58

Market Cap

198.9M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
RICK
CBIO
Founded
1983
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
207.0M
198.9M
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
RICK
CBIO
Price
$24.85
$13.58
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
6
Target Price
$98.00
$27.17
AVG Volume (30 Days)
88.4K
123.2K
Earning Date
02-09-2026
02-23-2026
Dividend Yield
1.12%
N/A
EPS Growth
252.84
N/A
EPS
1.86
N/A
Revenue
$281,738,000.00
N/A
Revenue This Year
$3.62
N/A
Revenue Next Year
$8.86
N/A
P/E Ratio
$13.46
N/A
Revenue Growth
N/A
N/A
52 Week Low
$21.88
$9.81
52 Week High
$57.99
$21.40

Technical Indicators

Market Signals
Indicator
RICK
CBIO
Relative Strength Index (RSI) 50.24 61.07
Support Level $24.04 $10.56
Resistance Level $27.01 $14.71
Average True Range (ATR) 1.13 0.86
MACD 0.06 0.35
Stochastic Oscillator 43.13 72.68

Price Performance

Historical Comparison
RICK
CBIO

About RICK RCI Hospitality Holdings Inc.

RCI Hospitality Holdings Inc through its subsidiaries owns and operates establishments that offer live adult entertainment, restaurant, and or bar operations. It also owns and operates a communication company serving the adult nightclub industry. The company's operating business segments are Nightclubs, Bombshells, and Others. It operates nightclubs through the following brands Rick's Cabaret, Vivid Cabaret, Tootsie's Cabaret, Club Onyx, and Jaguars Club. In the Bombshells segment, the company is building a chain of Restaurants and Sports Bars in Dallas, Austin, and Houston, Texas. It derives the majority of revenue from the Nightclubs segment that engages in the sale of alcoholic beverages, food, and merchandise items; service in the form of cover charges, dance fees, and room rentals.

About CBIO Crescent Biopharma Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: